The quality Targeting of Cancer Chemotherapy Using Non-Invasive Focused Resonance Nano-Permeabilization

Abstract

Focused Resonance Nano-permeabilization (FORN) (US Patent 9,616, 245 B2-Apr 11th 2017) enables the 'targeted' delivery of chemo-therapeutic molecules using a safe, non-invasive, whole-body therapeutic device. The prototype device houses a gantry with specialized, near field, radio-frequency (RF) antennae and guns to deliver instantaneous, magnetic resonance. Drug focusing and delivery was enabled using FORN in a patient with advanced, loco-regionally recurrent, metastatic, nasopharyngeal carcinoma (NPC). Nonionizing, safe, extraneous-source radio-frequencies (RF) were delivered in the presence of an instantaneous magnetic field, to create temporary drug molecular weight-specific nanopores in the cell membrane of target lesions, concurrently with systemic chemotherapy. The high frequency RF is timed and delivered to regions of interest (ROIs) to span peak plasma concentrations of infused chemotherapeutic drugs over multiple treatment cycles. FORN-enabled chemotherapy-related adverse event evaluation and tumor response based on PERCIST 1.0 reflected improved clinical, anatomical and metabolic outcomes and significantly reduced myelosuppression in the patient who received 6+1 Cycles of combination chemotherapy, over an extended period of time. Functional Assessment of Cancer Treatment-Head & Neck (FACT-H&N) / Quality of Life (QoL) and Karnofsky Performance Status (KPS) reflected overall patient well-being. Recurrent, loco-regional disease, nodal, hepatic and skeletal metastases showed dramatic response on PET-CT follow up. Concurrent chemo-radiotherapy (CCRT) as a treatment paradigm is the standard of practice in locally advanced nasopharyngeal carcinoma (NPC).